Clinical trials: Metastatic Prostate Cancer (mPC)
Prostate Cancer
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
The objective of this study is to examine the preference weightings in term of risk/ benefit attributes of treatment in physician and prostate cancer patients from different stages of disease.
- Trial name
- NCT05761093
- Where
- Hong Kong
- Volunteers
- 350 people
- Sponsor
- Chinese University of Hong Kong
Prostate Cancer, Advanced Prostate Cancer
European Registry of Next Generation Imaging in Advanced Prostate Cancer
The RING study is a European registry collecting real-world data on advanced prostate cancer (APC) imaging. It aims to evaluate the role of next-generation imaging (NGI), such as PET/CT and whole-body MRI, in detecting and…
- Conditions
- Prostate Cancer, Advanced Prostate Cancer, Metastatic Prostate Cancer (mPC)
- Trial name
- RING (NCT06866782)
- Testing
- Imaging
- Where
- 24 sites in Belgium, France and 6 more
- Volunteers
- 600 people
- Sponsor
- Fundacio Puigvert
Metastatic Prostate Cancer (mPC)
[68Ga]Ga-P17-079 in the Diagnosis and Treatment of Metastatic Prostate Cancer
Preclinical studies have confirmed that [68Ga]Ga-P17-079 in both mouse prostate tumors and osseogenic metastases has high uptake and prolonged retention, which enables [68Ga]Ga-P17-079 to be fully absorbed by the lesions, and it…
- Trial name
- NCT06864572
- Testing
- P17-079, P16-093, or P15-041 PET/CT
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking Union Medical College Hospital
Metastatic Prostate Cancer, Prostate Cancer
[18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)
This multicenter center, open-label, baseline-controlled diagnostic imaging study designed to assess the use of Fluorthanatrace-Positron Emission tomography (FTT-PET) as a PARP inhibitor (PARPi) therapy predictive imaging…
- Trial name
- NCT07723651
- Testing
- 1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one, FTT-PET/CT, EnhanceAR-Seq
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- Washington University School of Medicine
Metastatic Prostate Cancer (mPC)
Implementation of a New Algorithm for HRR Gene Mutation Testing in Patients With mPC Through Liquid Biopsy Integration
Implementation of a new algorithm for HRR gene mutation testing in patients with mPC through liquid biopsy integration
- Trial name
- L2-267 (NCT06762379)
- Where
- Italy
- Volunteers
- 125 people
- Sponsor
- European Institute of Oncology